Bird Flu News and Research

RSS

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

The habit of Googling for an online diagnosis before visiting a GP can provide early warning of an infectious disease epidemic.

18 Jan 2014

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

12 Dec 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

...

10 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists at the University of Maryland School of Medicine's Center for Vaccine Development are part of nationwide vaccine research aimed at protecting adults from a new and virulent strain of avian (bird) influenza (flu) virus.

20 Sep 2013

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists at Saint Louis University are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China last spring, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health (NIH) to test vaccines to protect against the illness in adults.

20 Sep 2013

Scientists prepare to test vaccines to protect against new bird flu strain

Scientists at Group Health Research Institute are preparing for the potential pandemic spread of a new bird flu strain that caused severe disease in China earlier this year, joining researchers from seven other Vaccine and Treatment Evaluation Units funded by the National Institutes of Health to test vaccines to protect against the illness in adults.

19 Sep 2013

Researcher characterises influenza A viruses in gulls and ducks

Ducks and gulls are the natural hosts of influenza A virus. Ragnhild Tønnessen's PhD research project has characterised influenza A viruses in gulls and ducks in Norway. Her discoveries may lead to a better understanding of the epidemiology and host adaptation of influenza A virus.

12 Sep 2013

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

BiondVax announced today that priming with universal flu vaccine before boosting with a conventional bird flu H5N1 vaccine (containing a single strain from Clade 1) resulted in mice exhibiting a significantly higher level of immunity to the strain contained in the conventional bird flu vaccine and in addition, broadened immunity to other H5N1 flu strains (from Clade 2).

27 Aug 2013

Strategy that dismantles flu viral genome in human lung cells ensures safe research

A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.

13 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.

2 Jul 2013

Bird Flu News and Research

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Internet surveillance helps detect infectious diseases earlier than traditional surveillance methods

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Vivaldi Buys Flu Vaccine R&D Assets From Baxter

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

Scientists aim at protecting adults from virulent strain of avian influenza virus

Scientists are preparing for possible pandemic spread of new bird flu strain

Scientists prepare to test vaccines to protect against new bird flu strain

Researcher characterises influenza A viruses in gulls and ducks

BiondVax: Priming with universal flu vaccine makes conventional bird flu vaccine effective against pandemic strains

Strategy that dismantles flu viral genome in human lung cells ensures safe research

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

Seattle researchers map critical molecules that regulate inflammation during flu infection

Study describes radiologic findings in H7N9 pneumonia

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Glycoproteins in saliva of older people are more efficient in binding to influenza

NanoViricides files Orphan Drug application with FDA for DengueCide

New computer model predicts when avian influenza strain becomes infectious

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News